Eli Lilly Acquires Psychedelic Drug Maker AtaiBeckley for $3.8 Billion to Expand Mental Health Portfolio

Eli Lilly, the world's most valuable pharmaceutical company, announced plans to acquire AtaiBeckley, a producer of psychedelic drugs for depression and anxiety treatment, for $3.8 billion. The deal includes $2.8 billion in cash and an additional $1 billion contingent on meeting predefined milestones. This acquisition values AtaiBeckley nearly $2 billion above Eli Lilly's market capitalization as of last Wednesday's closing price.

The move reflects Eli Lilly's strategy to invest revenues from its weight-loss drugs into early-stage scientific fields. AtaiBeckley, founded last year through a merger between Atai Life Sciences and British biotech Beckley Psytech, is advancing clinical trials for a 5-MeO-DMT spray targeting depression and an MDMA-based treatment for social anxiety. Billionaire Christian Angermayer, chairman and 14.5% owner, leads the combined company.

This acquisition aligns with a broader trend of major pharmaceutical firms, including AbbVie and Japan's Otsuka, acquiring biotech companies specializing in psychedelic therapies for mental health disorders. The growing acceptance of psychedelics is supported by U.S. government initiatives, such as a presidential order signed by Donald Trump in April to expedite FDA approval processes for psychedelic drugs.

Carol Ho, Eli Lilly's Vice President of Neuroscience, highlighted the urgent need for effective treatments for treatment-resistant depression, affecting millions worldwide. Analysts from BMO Capital Markets noted that the acquisition will add a fast-acting psychedelic treatment platform and broaden Eli Lilly's neuroscience portfolio to address resistant depression and other psychiatric disorders.

This deal is part of Eli Lilly's extensive biotech investments this year, totaling $28.8 billion, fueled by strong cash flows from its weight-loss and diabetes medications.